ArticleMolecular therapy. Nucleic acids2026
Development of gemcitabine-modified multimodal miR-129 mimic as a novel therapeutic in non-small cell lung cancer.
Article in Molecular therapy. Nucleic acids, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Engineering microRNAs as multimodal cancer therapeutics.Molecular therapy. Nucleic acids · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Resistance to chemotherapy and tyrosine kinase inhibitor (TKI)-based therapy is the main reason for treatment failure in non-small cell lung cancer (NSCLC). Therefore, there is an urgent need to develop novel strategies to combat resistance. In this study, we designed and developed a novel, multi-targeted microRNA (miRNA) approach to overcome resistance to EGFR inhibitors. Specifically, the guide strand of the tumor suppressor miR-129 was modified by replacing cytidine with the nucleoside analog gemcitabine (Gem). The therapeutic potential of Gem-miR-129 was investigated in both
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.